Device Trial Radar · NCT02636491
Use of an Automated Insulin Delivery System Compared to Sensor Augmented Pump at Patients With Type 1 Diabetes (T1D)
Last checked: Nov 19, 2026Latest source record: Feb 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Dec 2015
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- Kinderkrankenhaus auf der BultAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 21, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Title: An open-label, three-center, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control using the MD-Logic automated insulin delivery system compared to sensor augmented pump therapy at patients with type 1 diabetes at home Indication: Type 1 Diabetes mellitus using an insulin pump therapy and continues glucose sensors The objective of this pilot study is to evaluate the safety and efficacy of 60 hours blood glucose control, using the MD-Logic System in individuals with type 1 diabetes at patient's home. The duration of study participation for one subject is 28-56 days and the overall duration of the study is 6 months The participants of the study are patients ≥ 10 years until 65 years with Type 1 Diabetes mellitus using and insulin pump therapy and continuous glucose sensors. Sample Size n = 45
Conditions
- Type 1 Diabetes
Interventions
MD-Logic-Automated Insulin Delivery SystemDevice
Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller "OFF", this will automatically save the log file. The patient will return to his regular insulin treatment.
MiniMed Paradigm® Veo™ SystemDevice
Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
Primary outcomes
What the sponsor says the trial is designed to measure.
- normal glucose levelTime frame: 60 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kinder - und Jugendkrankenhaus AUF DER BULT
Hanover, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.